CME/CE INFORMATION

Rural Health Clinical Congress Fall 2024

Saturday, November 23, 2024 | Live CME/CE Conference
Broadcast starts at 8:00 AM CT


HOW TO CLAIM CREDIT
In order to obtain your CME/CE certificate(s), please follow the steps below at the conclusion of the event:

  • Step 1: Log In
    Access the event here. At the upper right corner, click Login and enter your username (the email address you used to register for the event) and password.
    If you do not know your password, follow the link to reset it.
  • Step 2: Complete Evaluation(s)
    Click the Evaluation link located in the gray navigation bar (under the event title). You will see a listing of the sessions. Click the blue Take Evaluation button and complete the evaluation form for each session you attended.
  • Step 3: View and Print Certificate(s)
    After you’ve completed the evaluations, click the Print Certificate button to view and print your CME/CE certificates.




Breathing Easier in Rural and Underserved Communities:
Evidence-Based Solutions for Improving COPD Care and Outcomes

Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT

This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.

This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Utilize evidence-based strategies to assess and identify uncontrolled symptoms of chronic obstructive pulmonary disease (COPD) and future risk of exacerbations
  • Develop a personalized treatment plan for patients with COPD based on current guideline recommendations and best practices
  • Evaluate the safety and efficacy of novel therapies for moderate-to-severe COPD
  • Implement evidence-based strategies to enhance COPD care and management in rural and underserved settings, including self-management tools, smoking cessation interventions, pulmonary rehabilitation services, and telehealth solutions

FACULTY
Nicola A. Hanania, MD, MS, FCCP
Professor of Medicine - Pulmonary
Director, Airways Clinical Research Center
Baylor College of Medicine
Chief of Pulmonary/Critical Care/Sleep Medicine
Ben Taub Hospital
Houston, TX

Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-068-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Nicola A. Hanania, MD, MS, FCCP, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., GSK, Sanofi, and Verona Pharma; speakers’ bureau member for Regeneron Pharmaceuticals, Inc. and Sanofi; contracted research for AstraZeneca Pharmaceuticals, Genentech, Inc., GSK, and Sanofi.

Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



Confronting Challenges in Moderate-to-Severe Asthma Management:
Optimizing Care Across All Ages in Rural and Underserved Communities


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.

This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Apply current guideline recommendations for assessment and management, including a stepwise approach to treatment and measures for classifying severity
  • Evaluate the latest clinical evidence on biologic therapies for children and adults with moderate-to-severe asthma
  • Identify patients with moderate-to-severe asthma who are appropriate candidates for biologic therapies based on clinical guidelines and characteristics
  • Use a patient-centered approach to educate patients on self-management and address their barriers to care

FACULTY
Nicola A. Hanania, MD, MS, FCCP
Professor of Medicine - Pulmonary
Director, Airways Clinical Research Center
Baylor College of Medicine
Chief of Pulmonary/Critical Care/Sleep Medicine
Ben Taub Hospital
Houston, TX

Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Pharmacotherapy credit for Advanced Practice Registered Nurses to be determined.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-070-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Nicola A. Hanania, MD, MS, FCCP, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., GSK, Sanofi, and Verona Pharma; speakers’ bureau member for Regeneron Pharmaceuticals, Inc. and Sanofi; contracted research for AstraZeneca Pharmaceuticals, Genentech, Inc., GSK, and Sanofi.

Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



Chronic Rhinosinusitis With Nasal Polyps Across the Continuum of Care:
A Collaborative Approach to Improving Outcomes in Rural and Underserved Settings


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.

This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. and Sanofi.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.25 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Apply current guidelines and criteria to improve the timely recognition and diagnosis of nasal polyps
  • Evaluate the mechanisms of action, safety, and efficacy of biologics in treating chronic rhinosinusitis with nasal polyps
  • Identify patients with nasal polyps who may be eligible for biologic therapy
  • Employ a multidisciplinary approach to ensure patients with chronic rhinosinusitis with nasal polyps have access to appropriate treatment and comprehensive care

FACULTY
Stella E. Lee, MD
Section Chief, Rhinology
Director, Brigham Sinus Center
Brigham and Women’s Hospital
Harvard Medical School
Boston, MA

Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-071-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Stella E. Lee, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AstraZeneca Pharmaceuticals, Genentech, Inc., Genzyme, GSK, Lyra Therapeutics, Novartis Pharmaceuticals Corporation, and Sanofi and Regeneron Pharmaceuticals, Inc.; contracted research for AstraZeneca Pharmaceuticals, Genentech, Inc., Genzyme, GSK, Lyra Therapeutics, Novartis Pharmaceuticals Corporation, OptiNose, Inc., and Sanofi and Regeneron Pharmaceuticals, Inc.

Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.




Advancing Early Detection and Treatment of Alzheimer’s Disease
in Rural and Underserved Communities: A Collaborative Approach


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.

This session is supported by an independent medical education grant from Eisai, Inc.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.25 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Differentiate signs and symptoms of early Alzheimer’s disease (AD) from those associated with normal aging
  • Incorporate evidence-based tools and strategies for screening and assessment of AD into routine clinical practice
  • Evaluate the latest clinical data on efficacy and safety of approved and emerging disease-modifying therapies (DMTs)
  • Utilize effective methods to improve access to care and collaborative management of patients with AD who reside in rural and underserved communities

FACULTY
Gary W. Small, MD
Chair of Psychiatry, Hackensack University Medical Center
Vice President, Behavioral Health Physician-in-Chief
H. Hovnanian Family Foundation Chair
Hackensack Meridian Health
Professor and Chair of Psychiatry & Behavioral Health
Hackensack Meridian School of Medicine
Hackensack, NJ

Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.25 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-072-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Gary W. Small, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Acadia Pharmaceutics, Inc., Allergan, Inc. (now AbbVie, Inc.), Biogen, Inc., Cogensus AI, Inc., Electro Cellular Healthcare Solutions, LLC, Handok, Inc., Lundbeck, Inc., Eli Lilly and Company, McCormick Science Institute, Merry Life Biomedical Company, Ltd., Otsuka America Pharmaceutical, Inc. (previously Avanir Pharmaceuticals, Inc.), R. Hoffman-La Roche, Ltd., and Theravalues.

Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



Envisioning Equity: Enhancing Access and Early Intervention for Retinal Disease
in Rural and Underserved Communities


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.

This session is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Implement effective strategies to enhance diabetic retinopathy screening and ensure timely referrals to specialists
  • Identify key symptoms and clinical characteristics of age-related macular degeneration
  • Evaluate clinical evidence on the efficacy, safety, and dosing profiles of available treatments for diabetic retinopathy
  • Incorporate shared decision-making and collaborative care practices to address and overcome barriers in managing patients with diabetic retinopathy and age-related macular degeneration

FACULTY
Yasha S. Modi, MD
Associate Professor of Ophthalmology
NYU Grossman School of Medicine
Director, Tele-Retina
New York, NY

Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-059-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Yasha S. Modi, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for AbbVie, Inc., Alcon, Inc., Alimera Sciences, Inc., Astellas Pharma, Inc., Dutch Ophthalmic Research Center, EyePoint Pharmaceuticals, Genentech, Inc., Neurotech Pharmaceuticals, Inc., Topcon Healthcare, Inc., Regeneron Pharmaceuticals, Inc., and ZEISS Group.

Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



Moderate-to-Severe Atopic Dermatitis: A Primary Care Approach
to Improving Equitable Access to Care in Rural and Underserved Communities


Provided by Talem Health and RME Collaborative:

custom image

ACKNOWLEDGEMENT
This initiative is co-supported by independent medical education grants from Eisai, Inc.; Regeneron Pharmaceuticals, Inc.; and Sanofi.

This session is supported by an independent medical education grant from Sanofi and Regeneron Pharmaceuticals, Inc.

CREDIT AVAILABLE

  • Physicians — maximum of 1.0 AMA PRA Category 1 Credit
  • Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
  • Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this activity will be issued a statement of participation.

TARGET AUDIENCE
This activity is designed specifically for primary care clinicians, registered nurses, and advanced practice registered nurses who care for patients from rural and underserved areas.

LEARNING OBJECTIVES

  • Evaluate the efficacy and safety of approved and emerging agents for moderate-to-severe atopic dermatitis (AD)
  • Identify common atopic and nonatopic comorbidities associated with AD in children and adults
  • Develop personalized treatment plans for adults and children with AD, considering comorbidities, disease severity, and patient-specific factors
  • Incorporate strategies for improving access to AD care in rural and underserved communities

FACULTY
Benjamin N. Ungar, MD
Assistant Professor of Dermatology
Director, Alopecia Center of Excellence
Director, Rosacea & Seborrheic Dermatitis Clinic
Icahn School of Medicine at Mount Sinai
New York, NY

Cody A. Chastain, MD, FACP, MEHP
Associate Professor of Medicine
Vanderbilt University Medical Center
Nashville, TN

JOINT ACCREDITATION STATEMENT

custom image

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

PHYSICIAN CONTINUING MEDICAL EDUCATION
Talem Health designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CONTINUING NURSING EDUCATION
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

CONTINUING PHARMACY EDUCATION
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-24-069-L01-P)
Type of Activity: Application

DISCLOSURE OF CONFLICTS OF INTEREST
Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty
Benjamin N. Ungar, MD, has disclosed the following relevant financial relationships: consultant/advisory board member for Bristol Myers Squibb, Fresenius Kabi, Galderma, Janssen Pharmaceuticals, Inc., Eli Lilly and Company, Pfizer, Inc., Primus Pharmaceuticals, Inc., Sanofi, and UCB; contracted research for Bristol Myers Squibb, Incyte Corporation, RAPT Therapeutics, Inc., Pfizer, Inc., and Sanofi.

Cody A. Chastain, MD, FACP, MEHP, has no relevant financial relationships to disclose.

Planners, Managers, and Reviewer
The Talem Health planners, managers, and reviewer have nothing to disclose.

DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.



CONTACT US

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.

MEDIA
Internet activity

COMPUTER SYSTEM REQUIREMENTS

  • System checker: Must meet all requirements of BroadcastMed Live Events Platform
  • Operating system: Windows or Macintosh
  • Supported browsers: HTML5-capable browser – Internet Explorer, Google Chrome, Mozilla Firefox, Safari, Microsoft Edge, Opera
  • Hardware: computer, smartphone, or tablet
  • Broadband Internet connection: high-speed connection preferable

FEE INFORMATION
There is no fee for this educational activity.

COPYRIGHT
©RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.